Private Label Eyelash Growth Serums:
Complete OEM Manufacturing Guide 2026

1. The Market: Why Lash Serums Are the Logical Next Product

The eyelash serum category occupies a uniquely attractive position in the beauty product landscape. Unlike lash extensions — which are a service-and-product bundle primarily distributed through professional channels (salons, lash artists) — serums are a retail product that can sell through professional channels, e-commerce (brand website, Amazon, TikTok Shop), beauty retailers (Sephora, Ulta, drugstores), and subscription boxes simultaneously. This multi-channel distribution flexibility means the addressable market for a lash serum brand is 3-5x larger than for a lash extension brand of comparable recognition.

The category's growth is being driven by several converging trends: post-extension lash damage recovery (consumers who have worn extensions for years are seeking serums to restore natural lash health — creating a built-in customer base for lash brands that already serve extension clients), the "skinification" of lash care (consumers now treat lash serums as part of their skincare routine, not a separate category — applying serum alongside moisturizer and eye cream), prostaglandin-free demand (consumer awareness of prostaglandin analog side effects — periorbital fat loss, iris darkening — is driving a massive shift toward peptide-based alternatives, creating market openings for brands that formulate without prostaglandins), and male grooming expansion (men's lash and brow serum usage grew ~35% year-over-year in 2025, driven by the broader "male beauty" normalization trend — men want longer, fuller lashes but will not wear extensions, making serum their primary lash enhancement option).

2. Formulation Pathways: Choosing Your Active Ingredient Strategy

The single most important product decision for a private label lash serum is the active ingredient strategy. Your choice of active ingredients determines your regulatory pathway, marketing claims, safety profile, manufacturing complexity, and competitive positioning. There are three primary formulation pathways in 2026:

2.1 Prostaglandin Analog Formulations (High Efficacy, High Regulatory Burden)

Prostaglandin analogs — including bimatoprost, latanoprost, travoprost, and their synthetic derivatives like isopropyl cloprostenate — are the most clinically effective lash growth compounds, capable of increasing lash length by 25-30% and density by 15-20% over 8-12 weeks of daily use. They work by extending the anagen (growth) phase of the lash hair cycle. However, in 2026, prostaglandin-based serums face significant headwinds: regulatory classification as OTC drugs in the US (requiring FDA NDA or ANDA — a multi-year, multi-million-dollar process), prescription-only status in most EU countries (bimatoprost is Rx-only; OTC cosmetic claims using "lash growth" language are prohibited if the product contains prostaglandins), growing consumer avoidance due to documented side effects (periorbital fat atrophy causing hollow-eye appearance, permanent iris darkening, eyelid skin hyperpigmentation), and retailer restrictions (Amazon, Sephora, and Ulta increasingly restrict or delist prostaglandin-containing lash serums). For a new brand entrant in 2026, the prostaglandin pathway is not recommended unless you have pharmaceutical-level regulatory capability and a tolerance for significant legal and reputational risk.

2.2 Peptide-Based Formulations (Recommended for 2026 Brand Launches)

Peptide-based lash serums use biomimetic peptides — short chains of amino acids that signal lash follicles to extend their growth phase — as the primary active ingredients. The leading lash peptides in 2026 formulations include Myristoyl Pentapeptide-17 (the most clinically studied lash peptide; stimulates keratin production in hair follicles), Biotinoyl Tripeptide-1 (binds to hair follicle receptors to extend anagen phase; also used in brow serums), Acetyl Tetrapeptide-3 (stimulates extracellular matrix proteins around the follicle for stronger anchoring), and Copper Tripeptide-1 (promotes collagen synthesis in the follicle microenvironment). Peptide formulations offer several strategic advantages for private label brands: they are cosmetically classified in all major markets (no drug registration required — cosmetic notification only), they are prostaglandin-free by design (enabling "prostaglandin-free," "hormone-free," and "no side effects" marketing claims), they have a strong safety profile (peptides are naturally occurring biological molecules; sensitization risk is low), and they are patent-unencumbered (peptide sequences cannot be patented — only specific delivery systems can, which means open access to active ingredients). The trade-off is that efficacy is moderate rather than dramatic: peptide serums typically deliver a 10-20% improvement in lash length and density over 8-12 weeks — visibly meaningful, but not the 25-30% that bimatoprost achieves. For the vast majority of consumers and the brands that serve them, this is the right trade-off: safe, legal, marketable efficacy without the regulatory and safety baggage of prostaglandins.

2.3 Natural/Botanical Formulations (Niche Positioning, Clean Beauty)

Botanical-based lash serums use plant extracts and natural compounds — castor oil (ricinoleic acid), biotin (vitamin B7), panthenol (provitamin B5), pumpkin seed extract, green tea polyphenols, ginseng extract, and amino acid complexes — as active ingredients. These formulations are positioned for the "clean beauty" and "natural" consumer segment. Efficacy is the lowest of the three pathways (5-10% improvement, primarily from improved lash conditioning rather than growth stimulation), but the marketing advantage is clear: "100% natural," "organic," "plant-based lash care" positioning resonates strongly with a specific consumer segment that will not buy synthetic peptide or prostaglandin products. These formulations are the simplest to manufacture and regulate, with the lowest per-unit cost, making them an attractive entry point for brands that want to test the serum category with minimal investment before committing to peptide development.

Formulation Pathway Comparison

3. Regulatory Roadmap: FDA MoCRA, EU CPNP, and Beyond

Regulatory compliance for lash serums is more complex than for lash extensions — you are manufacturing a cosmetic product with active ingredients applied near the eye, which triggers heightened regulatory scrutiny in every major market.

3.1 United States: FDA MoCRA

Under the Modernization of Cosmetics Regulation Act (MoCRA), cosmetic manufacturers — including private label lash serum brands — must: register their facility with the FDA (renewed biennially), submit a product listing for each serum SKU (including ingredients, responsible person contact, and product category), maintain safety substantiation records (documentation that the product is safe under labeled conditions of use — typically a toxicological risk assessment by a qualified safety assessor), comply with GMP requirements (FDA's cosmetic Good Manufacturing Practices, finalized 2025), and report serious adverse events (any health-related event associated with product use must be reported to FDA within 15 business days). Peptide-based and botanical serums fall under cosmetic classification if they make only cosmetic claims (e.g., "conditions and nourishes lashes," "promotes the appearance of fuller lashes"). Claims that the product "grows lashes" or "stimulates lash growth" trigger drug classification for prostaglandin-containing products, and regulatory gray-area risk even for peptide products — the safer marketing language is appearance-focused ("fuller-looking," "longer-appearing") rather than physiological ("grows," "stimulates").

3.2 European Union: EU CPNP + Cosmetics Regulation (EC) 1223/2009

EU market access requires: product notification in the CPNP (Cosmetic Products Notification Portal) before market placement, a Product Information File (PIF) maintained by a Responsible Person established in the EU, a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor (toxicologist or dermatologist with appropriate qualifications), and compliance with restricted and prohibited substances (Annex II and III of EC 1223/2009). Prostaglandin analogs are listed in Annex II (prohibited substances) for cosmetic use in the EU — they cannot be used in cosmetics, period. Peptide-based and botanical formulations face no such restrictions, making the EU market significantly more accessible for these formulation pathways. For additional context on EU beauty regulation, see our REACH Compliance for Eyelash Adhesives and EU CPNP Notification Guide.

3.3 Other Key Markets

Middle East (GCC): Saudi SFDA cosmetic notification required; Halal certification strongly recommended for GCC market positioning. Japan: PMDA cosmetic notification (yakubutsu-sho todoke); ingredient restrictions under Japan's Standards for Cosmetics (JSOC). South Korea: MFDS cosmetic product notification; functional cosmetic classification (kinoneungseong hwajangpum) for products making efficacy claims — requires additional testing. Latin America: ANVISA (Brazil) cosmetic registration for Grade 2 products (eye-area products are Grade 2); COFEPRIS (Mexico) cosmetic notification. Each of these markets has specific ingredient restrictions and documentation requirements — a qualified OEM manufacturer should provide regulatory documentation packages for each target market as part of their private label service.

4. OEM Manufacturing: How to Source Your Private Label Serum

4.1 Types of Serum Manufacturers

The lash serum contract manufacturing landscape includes three distinct types of suppliers: cosmetic formulation labs (specialists in peptide chemistry and eye-area formulations — the ideal partner for a peptide-based serum brand; typically have in-house R&D capability to customize formulations), full-service beauty OEMs (large manufacturers that offer formulation, filling, packaging, and regulatory support as a bundled service; higher MOQs — typically 5,000-10,000 units — but comprehensive support), and private label aggregators (companies that offer ready-made serum formulations with your label applied; fastest time to market, lowest MOQs — 500-1,000 units — but limited customization and lower margins because you are buying a pre-formulated product at a markup). The right choice depends on your brand stage, budget, customization requirements, and target market regulatory needs.

4.2 Key Manufacturing Quality Requirements

When evaluating serum OEM partners, insist on: GMP (ISO 22716) certification for cosmetic manufacturing, eye-area safety testing documentation (ocular irritation test — HET-CAM or BCOP assay; skin sensitization — HRIPT or LLNA; phototoxicity — 3T3 NRU PT), stability testing data (accelerated stability at 40°C/75%RH for 3-6 months + real-time stability at 25°C/60%RH for 12-24 months), preservative efficacy testing (challenge testing per USP <51> or ISO 11930 — critical for a product applied near the eye where bacterial contamination risk is high), and batch testing and COA documentation (every production batch should include a Certificate of Analysis verifying active ingredient concentration, pH, viscosity, microbial limits, and visual appearance).

4.3 MOQs and Unit Economics

5. Packaging and Branding: The 3ml Experience

Lash serum packaging serves three functions simultaneously: product protection (airless or controlled-dispense packaging to prevent active ingredient degradation from oxygen exposure), application precision (a fine-tip brush or wand that enables precise application along the lash line without product waste or eye contact), and brand signaling (the packaging is the product's physical embodiment of your brand positioning — luxury, clinical, natural, or minimalist). The most common packaging format is a 3ml airless pen with a fine brush tip — this format accounts for approximately 70% of the market because it protects peptide ingredients from oxidation (airless mechanism prevents air ingress), enables precise application, and creates a premium "pen-like" user experience that consumers associate with higher-value products. Packaging cost ranges from $0.40-1.20 per unit for standard designs to $2.00-4.00 for custom-molded, branded packaging with metallic accents, soft-touch finishes, or magnetic closures.

6. The Aurevia Perspective: Complementary, Not Competing

At Aurevia Lashes, our manufacturing focus is on premium private label lash extensions — from classic volume strips to premade fans, easy fans, colored lashes, DIY clusters, magnetic lashes, adhesive, and accessories. We do not manufacture lash serums in our Qingdao facility — serum manufacturing requires specialized cosmetic chemistry capability (formulation lab, stability chambers, preservative efficacy testing), which is a fundamentally different manufacturing competency from lash fiber production. However, we actively support our brand partners who want to expand into serums by providing introductions to our network of qualified cosmetic formulation labs, sharing regulatory intelligence for global markets, and coordinating lash + serum packaging co-design so that both product lines share a unified brand aesthetic. If you are sourcing private label lashes from our factory and want to add a complementary serum line, contact our team — we can connect you with the right manufacturing partner while ensuring your lash supply chain remains seamless.

Discuss Lash + Serum Product Strategy →

Also explore: OEM/ODM Private Label Lashes · Private Label Brand Guide · Branding Your Lash Line · Vegan & Cruelty-Free Guide